The estimated Net Worth of Investment Ltd China Molybd... is at least $3.16 Million dollars as of 19 February 2019. Investment Molybd owns over 200,000 units of TCR2 Therapeutics stock worth over $3,163,380 and over the last 6 years Investment sold TCRR stock worth over $0.
Investment has made over 1 trades of the TCR2 Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Investment bought 200,000 units of TCRR stock worth $3,000,000 on 19 February 2019.
The largest trade Investment's ever made was buying 200,000 units of TCR2 Therapeutics stock on 19 February 2019 worth over $3,000,000. On average, Investment trades about 200,000 units every 0 days since 2019. As of 19 February 2019 Investment still owns at least 2,137,419 units of TCR2 Therapeutics stock.
You can see the complete history of Investment Molybd stock trades at the bottom of the page.
Over the last 6 years, insiders at TCR2 Therapeutics have traded over $15,820,150 worth of TCR2 Therapeutics stock and bought 4,788,512 units worth $65,684,711 . The most active insiders traders include Group, Llc Green Jeremy Red..., Kevin Ctang Capital Managem..., and Ansbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $229,829. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth $86,000.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
TCR2 Therapeutics executives and other stock owners filed with the SEC include: